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Background: Unresectable pancreatic cancer (UPC) has low survival. With improving staging techniques and
systemic therapy, local control in patients without metastatic disease may have increasing importance. We
investigated whether the radiation dose used in chemoradiation (CRT) as definitive treatment for UPC and the CA
19–9 response to therapy have an impact on overall survival (OS).
Methods: From 1997–2009 46 patients were treated with CRT for non-metastatic UPC. Median prescribed RT dose
was 54 Gy (range 50.4-59.4 Gy). All patients received concurrent chemotherapy (41: 5-fluorouracil, 5: other) and 24
received adjuvant chemotherapy.
Results: 41 patients were inoperable due to T4 disease and 5 patients with T3 disease were medically inoperable.
Five patients did not complete CRT due to progressive disease or treatment-related toxicity (median RT dose
43.2 Gy). Overall, 42 patients were dead of disease at the time of last follow-up. The median and 12 month OS were
8.8 months and 35%, respectively. By univariate analysis, minimum CA 19–9 post-CRT <90 U/mL was favorably
associated with OS (12.3 versus 8.8 months, p = 0.012). Radiotherapy dose ≥54 Gy trended towards improved OS
(11.3 versus 6.8 months, p = 0.089). By multivariable analysis, a delivered RT dose of ≥54 Gy (HR 0.47, p = 0.028) and
minimum CA 19–9 post-CRT of <90 U/mL (HR 0.35, p = 0.008) were associated with OS.
Conclusions: CRT as definitive treatment for UPC had low survival. However, our retrospective data suggest that
patients treated to ≥54 Gy or observed to have a minimum post-CRT CA 19–9 <90 U/mL had improved likelihood
of long-term survival.
Keywords: Pancreas cancer, Radiotherapy dosage, Chemotherapy, CA-19-9 antigenBackground
Pancreatic cancer is the fourth leading cause of cancer-
related mortality in the United States with 43,140 new
cases and 36,800 deaths estimated in 2010 [1]. Approxi-
mately 50% of patients diagnosed with pancreatic cancer
have distant metastases at the time of diagnosis. Of the
remaining patients with local-regional disease, approxi-
mately 70% have tumors that are unresectable [2]. His-
torically, the prognosis for patients with unresectable
pancreatic cancer is low and the median survival with* Correspondence: sliauw@radonc.uchicago.edu
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reproduction in any medium, provided the orchemotherapy or chemoradiation (CRT) is between 8 to
12 months. Currently, treatment options for unresec-
table pancreatic cancer include CRT, chemotherapy
alone, and chemotherapy followed by CRT [3].
Chemotherapy alone or with concurrent radiotherapy
is a commonly accepted standard of care for unresec-
table pancreatic cancer because of the high risk of occult
distant metastases. However, the role of radiotherapy in
the treatment of unresectable pancreatic cancer is less
clear [4]. Radiotherapy as a component of treatment for
patients with unresectable pancreatic cancer is disputed
on the assumption that patients with pancreatic cancer
die of distant metastases. However, two autopsy studiesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with pancreatic cancer are due to locally progressive dis-
ease alone [5,6]. Retrospective [7] and prospective stud-
ies [8,9] support the hypothesis that CRT can improve
survival by decreasing local failure, although other stud-
ies are not confirmatory [4].
At the University of Chicago, patients with unresect-
able, non-metastatic pancreatic cancer are often treated
with CRT. We report our institutional experience using
CRT as definitive treatment for unresectable pancreatic
cancer by analyzing patient and treatment related factors
in relation to overall survival.
Methods
Between January 1997 and January 2010, 46 consecutive
patients were treated with definitive CRT for non-
metastatic unresectable pancreatic cancer at the University
of Chicago Medical Center. Patient characteristics are
summarized in Table 1. The University of Chicago Institu-
tional Review Board reviewed and approved this retro-
spective analysis. Patients were included if they were
treated with radiotherapy for unresectable pancreatic can-
cer. Nine patients were borderline resectable on staging
studies, but at the time of exploratory laparotomy were
deemed unresectable. Patients were not excluded from the
analysis if the treatment intent was curative but radiother-
apy was stopped before reaching the prescribed dose ei-
ther for toxicity or progression of disease.
Pretreatment evaluation
Patients were initially evaluated by a medical, surgical,
and radiation oncologist and their cases were discussed
at multidisciplinary tumor board. Patients were defined
as unresectable based on imaging including CT, MRI,Table 1 Patient and treatment characteristics stratified by rad
Number of patients












*T4 classification includes patients unresectable at exploratory laparotomy.
(BMI = body mass index; CRT = chemoradiation; IMRT = intensity modulated radiotand/or endoscopic ultrasound (n = 32) or intraoperative
exploration (n = 9) using the National Comprehensive
Cancer Network guidelines [10]. Five patients had T3
disease but were medically inoperable. One patient with
unresectable disease who was included in this analysis
was locally recurrent with unresectable disease 10 months
after previous resection. A total of 40 patients had a pre-
CRT CA 19–9 level. The median time from tissue diagno-
sis to the start of radiation therapy was 38 days. At least
one post-treatment CA 19–9 level was available in 39
patients.
Treatment
Table 1 summarizes the patient and treatment character-
istics for the groups treated with < or ≥54 Gy. None of
the patient characteristic or treatment parameters were
significantly different (p<0.05) between the low and high
dose groups and all subsequent analyses were done on
the entire cohort. Treatment characteristics are summar-
ized in Table 2. Overall, 46 patients were treated with
CRT for non-metastatic unresectable pancreatic adeno-
carcinoma. For simulation and treatment, patients were
immobilized with upper and lower cradles and a CT
simulation scan was obtained with 3 mm cuts. The me-
dian prescribed external beam RT dose was 54 Gy (range
50.4-59.4). Five patients did not complete CRT at a me-
dian RT dose of 43.2 Gy due to progressive disease (n = 2)
or treatment-related toxicity (n = 3).
Treatment techniques and approaches were based on
physician preference. Of the 46 patients, 30 (65%)
patients were treated with step-and-shoot IMRT. The
majority of patients treated with IMRT received sequen-
tial treatment of 45 Gy to the elective nodal region and
primary tumor, followed by a boost to the primaryiotherapy dose < or ≥ 54 Gy
All <54 Gy ≥54 Gy p value
46 21 25
61 63 59 0.089
26.5 26.8 25.9 0.757
37 16 21
9 5 4 0.506
5 2 3
41 19 22 0.788
24 12 12
22 9 13 0.536
43 21 22
3 0 3 0.101
16 10 6
30 11 19 0.094
herapy).
Table 2 Treatment characteristics
Prescribed RT dose, Gy
(median; range)
54; 50.4 – 59.4
Delivered RT dose, Gy
(median; range)
54; 18 – 59.4
Technique 3D-CRT 16
IMRT 30
Initial RT dose, Gy
(median; range)
45; 45 – 50.4
Boost RT dose, Gy
(median; range)
9; 5.4 – 14.4
Respiratory Gating Yes 6
No 40




(CRT = chemoradiation; Gy = Gray; IMRT = intensity modulated radiotherapy;
RT = radiotherapy; SD = standard deviation).
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treated with a simultaneous integrated boost of 55 Gy
(2.2 Gy/fraction) to the primary mass, and 45 Gy
(1.8 Gy/fraction) to the elective nodal region in 25 frac-
tions. Dose constraints for the whole liver (V30 <65%),
both kidneys (V20 <50%), and spinal cord (maximum
dose <45 Gy) were used for treatment planning. Patients
treated with 3D-conformal RT were generally treated
with a four-field technique with AP, PA, and opposed
lateral beams using a combination of 6 MV and 18 MV
photon beams with custom blocks and wedges as neces-
sary to increase dose homogeneity and spare normal tis-
sues and organs at risk. The initial treatment volume
included the gross tumor volume (GTV) and peripheral
draining lymphatics. Boost volumes included the pancre-
atic tumor and grossly involved lymph nodes. The GTV
to clinical target volume expansion was usually 1 cm ex-
cept into bone or muscle and an additional 1 cm was
added for the planning target volume expansion. 6 MV
photon beams were used for all IMRT treatments. Two
patients received neoadjuvant chemotherapy. All patients
received concurrent chemotherapy (5-fluorouracil con-
tinuous infusion n = 38, 5-fluorouracil bolus n = 3, cape-
citabine n = 2, gemcitabine n = 1, motexafin gadolinium
n = 2). Typical chemotherapy doses were either continu-
ous venous infusion 5-fluorouracil 150–200 mg/m2/day
for 96 hours every week, bolus 5-fluorouracil 500
mg/m2/day for 3 days during the first and last week
of radiation, capecitabine 1500 mg/m2 by mouth twice
daily throughout radiation therapy, gemcitabine twice
weekly at 40 mg/m2/day throughout radiation therapy,
and motexafin/gadolinium 2.9 mg/kg every Monday,
Wednesday, and Friday throughout radiation therapy. 13of the patients reported were enrolled on a randomized,
multi-institutional trial investigating TNFerade. The
radiotherapy dose for this trial was 50.4 Gy. In addition
to infusional 5-fluorouracil, 9 of the patients received
weekly intratumoral injections of TNFerade, a replication
deficient adenoviral vector used to deliver tumor necrosis
factor-α to the tumor cells. With the exception of the 13
patients enrolled on the TNFerade trial the selection of
radiation dose was dependent on physician preference.
Adjuvant chemotherapy was given at the discretion of
the treating medical oncologist. 24 patients received ad-
juvant chemotherapy (gemcitabine n = 20, 5-fluorouracil
n = 2, irinotecan/taxotere n = 1, and immunotherapy
n = 1). Nine patients did not receive adjuvant chemo-
therapy and adjuvant chemotherapy records were unavail-
able for 13 patients.
Follow-up
Patients were scheduled for follow-up at least every 3 to
4 months for the first 2 years. Computed tomography
scans of the chest, abdomen, and pelvis were obtained
prior to these visits to follow disease status. A CA 19–9
measurement generally was drawn at each follow-up.
The median time to the first CA 19–9 measurement fol-
lowing CRT was 34 days (range 3–347). Chemotherapy
was given at the medical oncologist’s discretion. Therapy
at the time of progression was per the treating medical
oncologist.
Endpoints
The primary endpoint of this study was overall survival.
Overall survival was determined by reviewing the social
security death index and hospital records. Secondary
endpoints included local and distant failure. Local and
distant failures were defined radiographically.
Statistical analysis
Overall survival time was calculated from the first day of
radiotherapy. Overall survival was censored at the date
of last follow-up recorded (clinic visit, radiographic
study, or laboratory value) if the patient remained alive.
The two-sided Student’s t-test was used to compare the
differences in means. Differences in proportions were
calculated using the chi-square test. Survival probabil-
ities were estimated using the Kaplan-Meier method.
The log-rank test was used to analyze survival differ-
ences between groups. Only variables trending towards
significance (p < 0.10) on univariate analysis were tested
in multivariable analysis. Cox proportional-hazards mod-
eling was used to examine the effect of radiotherapy
dose, CA 19–9 parameters, and other parameters on
overall survival. Stata v12.1 (StataCorp, College Station,
Texas) was used for all statistical analysis.
Table 3 Univariate analysis of patient and treatment
related factors in relation to overall survival
Median OS (months) p value
Age <60 8.8
≥60 7.0 0.778
T classification T3 4.9
T4 8.9 0.120
N classification N0 8.8
N1 8.9 0.543
Exploratory laparotomy No 8.9
Yes 8.5 0.550
Neoadjuvant chemotherapy No 8.8
Yes 6.6 0.814
RT dose delivered <54 Gy 6.8
≥54 Gy 11.3 0.089






CA 19–9 pre-CRT <90 U/mL 8.8
≥90 U/mL 8.8 0.626
CA 19–9 post-CRT minimum <90 U/mL 12.3
≥90 U/mL 8.8 0.012
(3D = three dimensional conformal radiotherapy; CA 19–9 = carbohydrate
antigen 19–9; CRT = chemoradiation; IMRT = intensity modulated
radiotherapy; RT = radiotherapy).
Figure 1 Overall survival for patients treated with < or ≥ 54 Gy
of radiotherapy. Note: two long term survivors are censored at 58
and 88 months.
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At the time of analysis, 42 of 46 patients were dead
of disease. The group included 19 men and 27
women. Tumors were located in the head (n = 31), body
(n = 11), tail (n = 1), head/body (n = 1), and body/tail
(n = 2). All but three patients had adenocarcinoma. The
other histologies included acinar cell carcinoma, ductal
carcinoma, and poorly differentiated carcinoma. The
median follow-up was 8.7 months for all patients, and
33.0 months for surviving or censored patients. A me-
dian of 38 days elapsed between pathologic diagnosis
and the start of RT. There was no correlation between
time from biopsy to start of CRT and overall survival
(p = 0.351). Median and 12 month overall survival
from the start of CRT were 8.8 months and 35.0% (95%
CI 21.4 – 48.9), respectively. 12 month freedom from
local failure and distant failure were 52% and 30%,
respectively.
Pre- and post-treatment CA 19–9 parameters were
evaluated. The median pre-CRT CA 19–9 was 343 U/
mL (range 0–18,955 U/mL). Because CA 19–9 levels
can be artificially elevated in the setting of biliary ob-
struction, the total bilirubin level at the start of CRT was
reviewed. Total bilirubin was normal (<1.2 mg/dL) for
all but eight patients at the start of CRT. Only two
patients had a total bilirubin >3 mg/dL the upper limit
of normal. A total of 15 patients had a pre-CRT
CA 19–9 ≤90 U/mL, and 24 had a pre-CRT CA 19–9
>90 U/mL. The median post-CRT CA 19–9 minimum
was 89 U/mL (range 0–25,744 U/mL). In patients who
had a post-treatment CA 19–9 value (n = 39), the me-
dian time to CA 19–9 minimum value was 66 days
(range 3–1,313 days).
Patient characteristics and treatment parameters were
analyzed in relation to overall survival with univariate
analysis (Table 3). The only prognostic factor signifi-
cantly associated with overall survival on univariate ana-
lysis was CA 19–9 post-CRT minimum <90 U/mL (≥90
U/mL 8.8 months versus <90 U/mL 12.3 months,
p = 0.012). Delivered radiotherapy dose ≥54 Gy trended
towards improved overall survival (≥54 Gy 11.3 months
versus <54 Gy 6.8 months, p = 0.089). There was no
difference in overall survival by tumor location, T classi-
fication, N classification, histology, pre-CRT CA19-9,
treatment on protocol, or treatment with TNFerade.
On multivariable analysis, delivered RT dose ≥54 Gy
(p = 0.028) and CA 19–9 post-CRT minimum <90 U/mL
(p = 0.008) were associated with overall survival (Figures 1,
2; Table 4). Patients who were treated to a total
dose ≥54 Gy and who experienced a post-CRT CA 19–9
minimum <90 U/mL had significantly longer survival than
all other patients (median 18.0 versus 8.6 months,
p = 0.002; Figure 3). A subset multivariable analysis ex-
cluding patients who did not complete RT (n = 5) showedthat post-CRT CA 19–9 minimum <90 U/mL remained
significantly associated with overall survival (p = 0.008)
and delivered RT dose ≥54 Gy continued to trend towards
improved overall survival (p = 0.065).
Figure 2 Overall survival for patients with CA 19–9 post-CRT
minimum ≥ or < 90 U/mL.
Figure 3 Overall survival for patients treated with ≥54 Gy of
radiotherapy and a CA 19–9 post-CRT minimum < 90 U/mL
versus all other.
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higher radiation dose would be attributable to improved
local control, an exploratory analysis of the effect radi-
ation dose on local failure was done. There were 5 local
failures in the <54 Gy patients and 9 local failures in
the ≥54 Gy patients (p = 0.82).
A recent study demonstrated improved outcomes in
patients with CA 19–9 levels <100 U/mL pre-CRT [11].
We therefore performed an exploratory subset analysis of
the effect of RT dose on survival in those patients who
had a pre-CRT CA 19–9 <90 U/mL (2.5x the upper limit
of normal). Median survival was higher for patients who
received a RT dose ≥54 Gy (12.3 versus 3.6 months), but
this difference was not statistically significant (p = 0.18),
related to the limited number of patients in this subset.
Discussion
The role for radiotherapy in the treatment of unresect-
able pancreatic cancer is controversial. For patients with
non-metastatic unresectable pancreatic cancer, data sup-
port the use of concurrent 5-fluorouracil and radiother-
apy with an improvement in overall survival [12]. Two
randomized studies also show a survival benefit to CRT
over chemotherapy alone [8,9]. However, other trials
have failed to show a benefit to the addition of radio-
therapy to chemotherapy [4]. In this single-institution
review of patients with non-metastatic unresectable pan-
creatic adenocarcinoma treated with definitive CRT, the
poor outcomes associated with this disease are observed.Table 4 Multivariable analysis of factors associated with
overall survival
HR (95% CI) p value
Delivered RT dose ≥54 Gy 0.47 (0.24-0.92) 0.028
CA 19–9 nadir <90 U/mL 0.35 (0.17-0.76) 0.008
(CA 19–9 = carbohydrate antigen 19–9; CI = confidence interval; HR = hazard
ratio; RT = radiotherapy).Our survival results are comparable to historical trials
[12]. We demonstrate a dose–response relationship, with
patients treated to ≥54 Gy surviving significantly longer
than those patients treated to <54 Gy. Analysis of the
two groups stratified by dose does not suggest that this
improvement is merely due to an imbalance of prognos-
tic factors.
The randomized trials for unresectable pancreatic can-
cer during the CT-imaging era used radiotherapy doses
between 50.4 and 60 Gy. The previously tested dose of
60 Gy was only studied with split-course radiotherapy,
which decreases the biological effectiveness in compari-
son to continuous treatment. The data presented suggest
that with higher doses of continuous radiotherapy, the
benefit of radiotherapy may be more substantial. Meth-
ods to increase the radiotherapy dose delivered to the
pancreas have included intra-operative radiotherapy
(IORT), stereotactic body radiotherapy (SBRT), intensity
modulated radiotherapy (IMRT), and image-guided
radiotherapy (IGRT). However, none of the methods
have been evaluated in phase III trials.
Long-term survivors have been reported in a study using
IORT [13]. IMRT has also been demonstrated to decrease
the dose to critical structures without compromising
tumor control [14]. A recent study investigating radiother-
apy dose escalation using IMRT and active breathing con-
trol with gemcitabine showed promising 2-year freedom
from local progression and overall survival of 59% and
30%, respectively [15]. SBRT is also a promising technique
for dose escalation. In one study of IMRT with a SBRT
boost to the primary tumor, local control was seen in
15/16 patients until death [16]. Results with primary SBRT
have been mixed, with good rates of local control but sig-
nificant toxicity and distant failure resulting in survival
rates that are not superior to historical controls [17-21].
Further improvement of techniques such as these may
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the tumor while sparing normal tissue, thereby increasing
the therapeutic ratio of radiotherapy. Our institution cur-
rently has an ongoing SBRT dose escalation protocol for
unresectable pancreatic cancer.
In our current study, we demonstrated an improve-
ment in overall survival with higher radiation dose, but
were unable to show a corresponding improvement in
local control with higher radiation dose. Given that our
medical center is a tertiary referral center, many patients
return to their local institutions after treatment for
follow-up imaging. Therefore, the local and distant fail-
ure data are less robust that the survival data. In
addition, it is important to emphasize that although the
crude rate of local failure was higher in the ≥54 Gy
patients, these patients were followed for slightly longer
periods of time and may have had a greater opportunity
to define local failure. This observation may explain why
this difference was not significant on actuarial analysis.
Recent studies have examined induction chemotherapy
followed by concurrent CRT as a method to select those
patients most likely to benefit from aggressive local
treatment with concurrent CRT [7,22,23]. These studies
show improved outcomes in patients who complete in-
duction chemotherapy and subsequently receive CRT.
The GERCOR study treated patients to 55 Gy with
45 Gy administered in 1.8 Gy fractions daily and an add-
itional 1.25 Gy four days per week for the final two
weeks as a second daily dose [7]. Another study reported
preliminary results from 28 patients treated with induc-
tion chemotherapy followed by 44.25 Gy in 15 fractions
with concomitant capecitabine and demonstrated an
18 month overall survival of 63% [24]. Patients who do
not progress through neoadjuvant chemotherapy are
selected as a biologically favorable group without the
propensity for early progression of metastases; the rate
of distant metastasis after induction chemotherapy
is approximately 30% in the two prospective trials.
Radiotherapy dose escalation therefore may be able to fur-
ther improve outcomes in patients not already harboring
micrometastatic disease, as local therapy would presum-
ably have a relatively higher impact in these patients. Re-
view of the patterns of failure for the patients completing
induction chemotherapy and CRT in the UCSF prospect-
ive study [22] show that 33% failed locally as first site of
failure. Radiotherapy dose escalation for this subset of
patients may delay or prevent recurrence, and thereby im-
prove survival. Another possibility would be to test tumor
tissue obtained at the time of biopsy for radiosensitivity,
similar to a recent study that evaluated sensitivity to gem-
citabine in vitro [25], to select patients most likely to bene-
fit from aggressive local therapy.
Data from borderline resectable patients procee-
ding to curative resection also supports radiation doseescalation. The University of Virginia treated 8 patients
with 50.4 Gy in 28 fractions and concurrent capecitabine
and 8 patients with a hypofractionated regimen (50 Gy
delivered in 20 fractions) and concurrent capecitabine
prior to surgery. 50 Gy in 20 fractions offers a higher
biologically equivalent radiation dose. Five of the 8
patients who underwent resection showed a >90%
pathologic complete response in the hypofractionated
group versus 1 of 8 patients in the standard fraction-
ation group, suggesting that dose escalation with
hypofractionation improves pathologic response [26].
We also demonstrated that a CA 19–9 minimum <90
U/mL (2.5x the upper limit of normal) is associated with
improved survival. Prior studies have demonstrated that
CA 19–9 levels can predict response to CRT and can be
prognostic for outcome in the unresectable setting
[11,25,27,28]. Yoo et al. [11] recently demonstrated that
a CA 19–9 level <100 U/mL before or after CRT for
unresectable pancreatic cancer is prognostic for overall
survival. Our finding that a CA 19–9 level <90 U/mL
after CRT supports the finding that a low CA 19–9 level
after CRT for unresectable pancreatic cancer is prognos-
tic for survival. It has been shown in the resectable set-
ting that patients with high pre-operative CA 19–9
levels who experience normalization of their post-
operative CA 19–9 levels had similar outcomes to those
patients with low pre-operative CA 19–9 levels [29].
This suggests that CA 19–9 response in the definitive
CRT setting may be a surrogate for local tumor control
which in turn may predict for improved survival. We did
not find an association between pre-treatment
CA 19–9 and survival. However, we did demonstrate a
trend towards improved survival with a delivered
RT dose >54 Gy in patients who had a pre-CRT
CA 19–9 <90 U/mL, suggesting that RT dose escalation
in patients with lower tumor burden [11] may improve
outcomes. Given the small number of patients in our
subset, the difference in survival did not reach statistical
significance.
This study has several limitations. First, this is a retro-
spective series subject to selection bias, in which the
more favorable outcomes of patients treated to higher
RT dose could potentially be due to uncontrolled factors
and an improved ability to complete therapy. Although
higher RT dose continued to trend towards improved
survival upon exclusion of patients with incomplete
courses of therapy, we are unable to exclude the possi-
bility of a bias that more favorable patients were pre-
scribed, or could tolerate, higher doses. Additionally,
many patients diagnosed with locally advanced pancre-
atic cancer develop systemic metastases or progressive
local disease and are not referred for radiotherapy.
Therefore, the patients analyzed here may represent a
selected group of patients with locally advanced
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of toxicity data due to a lack of reliable grading of
toxicity and limited follow-up. However, in those
patients with >1 year of follow-up before death, there
did not appear to be an increase in late toxicity in the
high versus low radiotherapy dose groups. Also, the two
long term survivors, both treated with doses of 59.4 Gy,
are alive without grade 2+ gastrointestinal toxicity.
Nevertheless, the risk for increased toxicity should be
carefully weighed against the potential for improved sur-
vival when considering dose escalated RT.
In conclusion, patients treated with CRT as definitive
treatment for unresectable pancreatic cancer generally
had low survival. However, our data suggest that patients
treated with ≥54 Gy or who experienced a post-CRT CA
19–9 minimum <90 U/mL had an improved likelihood
of long-term survival. The results presented herein sup-
port the use of dose-escalated radiotherapy combined
with systemic chemotherapy as a component of defini-
tive treatment for unresectable pancreatic cancer. We
are hopeful that through a combination of improving
systemic chemotherapy, novel biologic agents, and tar-
geted local therapy including dose-escalated radiother-
apy, outcomes for patients with unresectable pancreatic
cancer may improve.
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